Forest Sees “Moderate” Namenda Growth Opportunity In Mild Alzheimer’s
Executive Summary
Forest expects approval of its Namenda sNDA for the treatment of mild-to-moderate Alzheimer's disease to generate a "modest uptick" in prescription volume in the second half of the year
You may also be interested in...
Ortho McNeil Neurologics To Promote Razadyne (Formerly Reminyl)
Johnson & Johnson is changing the name of Reminyl (galantamine) to Razadyne in advance of the launch of an extended-release version of the Alzheimer's product
Forest Namenda Has 10% Off-Label Use In Mild-To-Moderate Alzheimer’s
Forest's Alzheimer's disease agent Namenda has 10% off-label use based on early launch data
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011